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A B S T R A C T
Purpose
The TAXYNERGY trial (ClinicalTrials.gov identiﬁer: NCT01718353) evaluated clinical beneﬁt from
early taxane switch and circulating tumor cell (CTC) biomarkers to interrogate mechanisms of
sensitivity or resistance to taxanes inmenwith chemotherapy-naı¨ve,metastatic, castration-resistant
prostate cancer.
Patients and Methods
Patients were randomly assigned 2:1 to docetaxel or cabazitaxel. Men who did not achieve $ 30%
prostate-speciﬁc antigen (PSA) decline by cycle 4 (C4) switched taxane. The primary clinical endpoint
was conﬁrmed $ 50% PSA decline versus historical control (TAX327). The primary biomarker
endpoint was analysis of post-treatment CTCs to conﬁrm the hypothesis that clinical response was
associated with taxane drug-target engagement, evidenced by decreased percent androgen re-
ceptor nuclear localization (%ARNL) and increased microtubule bundling.
Results
Sixty-three patients were randomly assigned to docetaxel (n = 41) or cabazitaxel (n = 22); 44.4%
received prior potent androgen receptor–targeted therapy. Overall, 35 patients (55.6%) had
conﬁrmed $ 50% PSA responses, exceeding the historical control rate of 45.4% (TAX327). Of 61
treated patients, 33 (54.1%) had $ 30% PSA declines by C4 and did not switch taxane, 15 patients
(24.6%) who did not achieve$ 30% PSA declines by C4 switched taxane, and 13 patients (21.3%)
discontinued therapy before or at C4. Of patients switching taxane, 46.7% subsequently achieved
$ 50% PSA decrease. In 26 CTC-evaluable patients, taxane-induced decrease in %ARNL (cycle
1 day 1 v cycle 1 day 8) was associated with a higher rate of$ 50% PSA decrease at C4 (P = .009).
Median composite progression-free survival was 9.1 months (95% CI, 4.9 to 11.7 months); median
overall survival was not reached at 14 months. Common grade 3 or 4 adverse events included
fatigue (13.1%) and febrile neutropenia (11.5%).
Conclusion
The early taxane switch strategywas associatedwith improved PSA response rates versus TAX327.
Taxane-induced shifts in %ARNL may serve as an early biomarker of clinical beneﬁt in patients
treated with taxanes.
J Clin Oncol 35:3181-3188. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Taxanes are the only class of chemotherapy agents
that extend survival in men with advanced
prostate cancer.1-4 These drugs bind b-tubulin
and stabilize cellular microtubules, leading to
inhibition of microtubule-dependent intracellu-
lar trafﬁcking and signaling, mitotic arrest, and
apoptotic cell death.5-7 Although taxanes are
generally considered antimitotic agents, they also
inhibit tumor growth via several different
mechanisms.5 Prostate cancer cells rely heavily
on sustained androgen receptor (AR) nuclear
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signaling, which drives progression despite androgen-deprivation
therapy.8 It was recently discovered that AR binds to cellular
microtubules via the microtubule-associated motor protein dynein
to facilitate its nuclear translocation.9 Taxanes can therefore inhibit
AR nuclear trafﬁcking via stabilization of microtubules; taxane-
induced microtubule stabilization (termed drug-target engage-
ment [DTE]) results in microtubule bundling (MTB), cytoplasmic
sequestration of AR, inhibition of AR transcriptional activity, and
inhibition of prostate cancer cell growth.6,7 In summary, the ef-
fectiveness of taxanes in prostate cancer can, at least in part, be
attributed to the inhibition of AR signaling.9
Overcoming primary (intrinsic) and secondary (acquired)
resistance to taxane therapy remains a challenge in prostate cancer
treatment, and several different mechanisms of taxane resistance
have been proposed (many of which may operate simulta-
neously).10-13 However, because cabazitaxel retains activity in
many docetaxel-refractory patients with metastatic castration-
resistant prostate cancer (mCRPC), there is evidence to suggest
that not all of the same resistance mechanisms apply to all tax-
anes.14-17 Therefore, the central clinical hypothesis of this study
was that some patients with mCRPC with a suboptimal initial
prostate-speciﬁc antigen (PSA) decline with their ﬁrst taxane can
subsequently achieve a PSA response by an early switch to a second
taxane before clinical progression.
Circulating tumor cells (CTCs) isolated from the blood of
patients with mCRPC can serve as a powerful tool to study
mechanisms of taxane sensitivity and resistance and can provide
a liquid biopsy for serial tumor analysis.18,19 Recently developed
microﬂuidic capture techniques enable reliable isolation of CTCs
from peripheral blood, which can be analyzed using functional and
molecular assays.20 Our central biomarker hypothesis was that
CTCs can be used to interrogate AR localization and MTB to
determine an association with response in men treated with
a taxane.
In the current study (TAXYNERGY; ClinicalTrials.gov identi-
ﬁer: NCT01718353), we prospectively evaluated the beneﬁt of an
early switch from docetaxel to cabazitaxel or vice versa using early
PSA changes (in the ﬁrst 12 weeks of therapy) as a predictor of
clinical efﬁcacy or therapeutic resistance. In parallel, CTCs were
analyzed at the single-cell level, using DTE criteria to assess whether
CTC-speciﬁc DTE correlated with sensitivity to taxane treatment on
an individual basis. The study met its primary objectives by dem-
onstrating a beneﬁt for early taxane switch as evaluated by conﬁrmed
PSA responses and an association of response with early changes in
AR nuclear localization (ARNL) in CTCs.
PATIENTS AND METHODS
Patient Population and Study Design
TAXYNERGYenrolled chemotherapy-naı¨ve patients with progressive
mCRPC and an Eastern Cooperative Oncology Group performance score
(ECOG PS) of 0 to 2, with no prior b isotope therapy, whole pelvic ra-
diotherapy, or radiotherapy to . 30% of bone marrow. Patients with
neuropathy grade . 2 were excluded. Prior hormonal therapy (including
potent CYP17 inhibitors and AR signaling inhibitors) and immunotherapy
were allowed.
In this noncomparative randomized study, patients were randomly
assigned 2:1 to initiate docetaxel 75 mg/m2 or cabazitaxel 25 mg/m2 every
3 weeks plus daily prednisone 10 mg. The study was initially designed
shortly after the US Food and Drug Administration approval of cabazitaxel,
and conservatively, it was decided to have more patients receive docetaxel
followed by cabazitaxel (the approved sequence) with the primary analysis
in that cohort. With ﬁve patients enrolled, the protocol was amended,
under the hypothesis that the two taxanes had similar activity in the ﬁrst-
line setting, to reduce the sample size and to pool both random assignment
arms in the primary clinical and biomarker analyses while maintaining
adequate power. Enrollment continued for 10 months after the amend-
ment up to a total of 63 patients; study data and random assignment
remained blinded during this time.
Patients achieving a$ 30% PSA decline from baseline by cycle 4 (C4;
week 12) continued to receive the same chemotherapy agent, whereas those
who did not achieve a $ 30% PSA decline were switched to the other
taxane (Fig 1A). Patients could also switch taxanes for radiologic pro-
gression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.121
in measurable lesions, regardless of PSA change. Switch could only occur at
cycle 5 (C5). Treatment continued until disease progression, death, un-
acceptable toxicity, or withdrawal of consent.
The study was approved by the institutional review board at each
participating center and conducted in compliance with guidelines for
Good Clinical Practice. Patients provided written informed consent before
participation.
Efficacy Assessments
The primary clinical endpoint was PSA response rate, deﬁned as the
proportion of patients who achieved a$ 50% PSA decrease from baseline,
conﬁrmed 3 weeks later,22 whether a treatment switch occurred. Secondary
efﬁcacy assessments included progression-free survival (PFS; deﬁned as the
time from random assignment to the ﬁrst of the composite endpoints:
PSA, radiographic, or clinical progression or death) and overall survival
(OS; deﬁned as the time from random assignment to death). PSA mea-
surements were taken every 3 weeks, and radiologic evaluations (chest,
abdomen, and pelvis computed tomography; whole-body bone scan) were
performed every 12 weeks until radiologic tumor progression or study
cutoff.
The coprimary efﬁcacy endpoint was DTE. CTCs were isolated at
speciﬁed time points (Fig 1A) using geometrically enhanced differential
immunocapture,20 immunostained, and analyzed for CTC-speciﬁc bio-
markers using multiplex confocal microscopy (Data Supplement). CTCs at
baseline (cycle 1 day 1 [C1D1]) were compared with CTCs isolated after
1 week of treatment (cycle 1 day 8 [C1D8]) for percent ARNL (%ARNL)
and MTB. %ARNL was determined by quantiﬁcation of integrated AR
staining intensity in the total cell and nucleus areas. MTB was qualitatively
assessed by three independent operators for increase compared with C1D1
on a scale of 0 to 3 from no tomostMTB increase. Findings were correlated
with clinical parameters for all CTC-evaluable patients.
Safety Assessments
Safety assessments included ongoing analysis of adverse events and
serious adverse events (National Cancer Institute Common Terminology
Criteria for Adverse Events v.4.03),23 vital signs, physical examinations,
ECOG PS, and laboratory ﬁndings (hematology, serum biochemistry,
coagulation, and urinalysis).
Statistical Considerations
Sample size determination was based on a historical PSA response
rate of 45.4% from the intent-to-treat population in the TAX327 study.1 In
TAXYNERGY, we reasoned that a 25% relative improvement in PSA re-
sponse rate to 58% using the early-switch strategy would be clinically
meaningful, and an estimate of the response rate with a one-sided 90% CI
was calculated. The trial would be considered successful if the lower bound
of the one-sided 90% CI did not contain the TAX327 PSA response rate of
45.4% (with 60 patients, the width of the one-sided 90% CI was 8.2%).
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The main focus of the biomarker analyses was the change between
C1D1 and C1D8 in %ARNL and MTB and its association with PSA
($ 50%) response. Additional exploratory analyses examined other in-
tervals (including change between pretreatment and C5 and PSA decline
by$ 30%). Absolute differences, and differences separated into categories,
were examined by analysis of variance and waterfall plots.
Secondary clinical endpoints were analyzed by descriptive statistics
and survival techniques. PSA response rates were reported. Time-to-event
endpoints (PFS and OS) were evaluated using Kaplan-Meier curves
and 95% CIs. All statistical tests were two-sided, with a signiﬁcance level of
P , .05. Analyses were performed using SAS 9.3 software (SAS Institute,
Cary, NC).
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Fig 1. (A) Study design. (B) CONSORT
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prostate cancer; PI, principal investigator;
PSA, prostate-speciﬁc antigen.
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RESULTS
Patient and Treatment Characteristics
Between November 2012 and June 2014, 63 patients were
randomly assigned to initial docetaxel (n = 41) or cabazitaxel
(n = 22), and 61 patients received treatment (Fig 1B). Two patients
initially randomly assigned to receive docetaxel did not receive
treatment as a result of withdrawal of consent.
Baseline patient and disease characteristics are provided in the
Data Supplement. Median age was 71 years; most patients had an
ECOG PS $ 1 (66.7% and 4.8% had ECOG PS of 1 and 2, re-
spectively). Median PSA was 82.30 ng/mL, and 34.9% of patients
had visceral metastases. In total, 28 patients (44.4%) received prior
treatment with potent AR-targeted therapy. The mean duration of
study treatment was 26.1 weeks (median, 27 weeks; range, 3.1 to
60 weeks); the mean number of cycles was 8.4. The most common
reasons for treatment discontinuation were disease progression
(n = 21, 34.4%), adverse event (n = 17, 27.9%), and investigator
decision (n = 14, 23.0%; Data Supplement).
Primary Efficacy EndPoint and PSA Changes From
Baseline
The primary endpoint of this study was PSA response rate,
deﬁned as the proportion of randomly assigned patients who
achieved a conﬁrmed $ 50% PSA response during the whole
treatment continuum, before treatment switch and after treatment
switch, if applicable. Across the entire treatment continuum by
intent-to-treat analysis, 35 (55.6%) of 63 patients achieved a$ 50%
PSA response; 25 patients (39.7%) achieved the response on or
before C4, and 10 patients (15.9%) achieved the response after C4.
The lower limit of the 90% one-sided CI was 47.5%, which did not
overlap with the rate of 45.4% in TAX327.1 Therefore, the primary
clinical endpoint was met. The PSA response rates in men who had
and had not received prior potent AR-targeted therapy were 44% (11
of 25 patients) and 68% (24 of 35 patients), respectively (P = .069).
Of 61 treated patients, 15 (24.6%) switched treatment after C4
as a result of an early PSA reduction , 30% (n = 14) or radio-
graphic progression (n = 1) and were treated with the alternative
taxane. Thirty-three patients (54.1%) achieved early $ 30% PSA
reduction and remained on their initial taxane, and 13 patients
(21.3%) discontinued treatment before C5 (Table 1). Of the 15
patients who switched, seven (46.7%) subsequently achieved a PSA
response. Changes in PSA from baseline per patient are shown in
the Data Supplement.
Secondary Efficacy Endpoints
Median composite PFS was 9.1 months (95% CI, 4.93 to
11.70 months; Fig 2A). Median radiographic PFS and OS were not
reached; after a median follow-up of 14 months,. 50% of patients
were still alive (Fig 2B). PSA PFS is shown in the Data Supplement.
Biomarker Analysis: Nuclear AR Localization and
Tubulin Bundling in CTCs
Of 60 patients who had PSA assessment, 44 had evaluable
CTCs at C1D1, 31 had evaluable CTCs at C1D8, and 25 had
evaluable CTCs at both C1D1 and C1D8. This analysis was based on
mechanistic studies showing that taxanes impair ARNL downstream
of microtubule stabilization.6,7 Therefore, we calculated %ARNL at
C1D1 and C1D8 and assessed whether a decrease in%ARNL at C1D8
was associated with PSA response. There were no signiﬁcant cor-
relations between baseline biomarker parameters and any clinical
outcomes (data not shown). Figure 3 shows representative high-
resolution images of CTCs captured by geometrically enhanced
differential immunocapture with high and low%ARNL. After 1 week
of taxane therapy (C1D8), mean %ARNL was signiﬁcantly lower in
patients who subsequently achieved a $ 50% PSA reduction at C4
versus those without PSA response (44.0% v 64.1%, respectively;
P = .004; Data Supplement). PSA responses were more common in
patients with %ARNL at C1D8 that was in the lower three quartiles
than in patients with %ARNL in the upper quartile (Fig 4A). By
C1D8, mean %ARNL decreased by 17.6% in patients with $ 50%
PSAdecrease and increased by 2.3% in patients without a$ 50%PSA
decrease (P = .020). A taxane-induced decrease in mean %ARNL
(C1D8 v C1D1) was associated with a higher rate of $ 50% PSA
decrease (72.7% v 12.5% of patients with no decrease in mean %
ARNL; P = .009). PSA responses were also more common in patients
with decreasingmean%ARNL at C1D8 compared with C1D1 than in
men with increasing mean %ARNL (Fig 4B). In exploratory analysis
of %ARNL at C5 day 1 to C5 day 8 after taxane switch, mean%ARNL
decreased (74.26 at C5 day 1 to 63.84 at C5 day 8; P = .05).
At C1D8, mean increase in MTB was numerically higher in
patients who achieved an initial $ 30% PSA decrease compared
with nonresponders, although this did not achieve statistical sig-
niﬁcance (0.69 v 0.09, respectively; P = .093). Taxane-induced
increase in mean MTB score trended toward an association with
response and was observed in patients who did not require a taxane
switch after C4, but this did not achieve statistical signiﬁcance (0.75
v 0.09 in those who required a switch; P = .059; Data Supplement).
Safety
Treatment-emergent adverse events (TEAE) leading to per-
manent treatment discontinuation were reported in 17 patients
(27.9%) and were possibly related to the study drugs in 13 patients
(21.3%). Dose modiﬁcation as a result of a TEAE was reported in
27 patients (44.3%). The most frequently reported TEAEs in all
patients were fatigue, diarrhea, and nausea (67.2%, 55.7%, and
41.0% overall, respectively; Table 2).
The most frequent grade 3 or 4 TEAEs were febrile neu-
tropenia and fatigue. There were two deaths as a result of TEAEs,
both in docetaxel-treated patients; one death was a result of an
Table 1. Summary of Patients by Treatment and Taxane Switch (treated
population)
Switch Status
No. of Patients (%)
All
Patients
(N = 61)
Cabazitaxel
(n = 22)
Docetaxel
(n = 39)
No taxane switch 46 (75.4) 19 (86.4) 27 (69.2)
No switch after cycle 4 33 (54.1) 13 (59.1) 20 (51.3)
Switch not applicable* 13 (21.3) 6 (27.3) 7 (17.9)
Taxane switch 15 (24.6) 3 (13.6) 12 (30.8)
*Patients who discontinued treatment before cycle 5.
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unrelated septic shock, and the other was reported as a possibly
related myocardial infarction. Serious adverse events and dose
modiﬁcations are summarized in the Data Supplement.
DISCUSSION
TAXYNERGY was conducted to test the clinical hypothesis that
switching taxane therapy in men who do not achieve an optimal
PSA reduction in the ﬁrst 12 weeks of therapy may improve clinical
outcomes and subvert resistance. Our primary biomarker hy-
pothesis was that ARNL and MTB could be assessed reliably from
CTCs and would be associated with outcome in patients treated
with taxanes. The conﬁrmed PSA response rate observed using the
switch strategy (55.6%) was superior to the prespeciﬁed historical
control trial (TAX327).1 Importantly, 46.7% of men who did not
achieve a $ 30% PSA reduction in the ﬁrst 12 weeks of treatment
subsequently achieved a$ 50% PSA response by switching taxane
therapy.
In addition, biomarker analyses from CTCs corroborated
emerging preclinical data that taxanes may mediate some of their
activity in prostate cancer by impairing AR trafﬁcking along the
microtubules from the cytoplasm into the nucleus, whereas per-
sistent nuclear AR localization despite taxane therapy may be
a marker of primary or early acquired resistance.6,7,9 To our
knowledge, this is the ﬁrst prospective trial to report changes in
ARNL and MTB in CTCs in patients with prostate cancer receiving
taxane therapy, and this trial has demonstrated the feasibility of
conducting a biomarker-rich trial across multiple US and Cana-
dian sites. Initial exploratory analyses of %ARNL and MTB in
CTCs as a marker of DTE suggest a potential association with
sensitivity to taxane therapy. To this end, the totality of the data
from TAXYNERGY suggest that although these baseline biomarker
parameters are not prognostic for clinical outcomes to chemo-
therapy, dynamic taxane-induced changes in ARNL (and perhaps
MTB) may be indicative of beneﬁt. More speciﬁcally, a decrease in
nuclear-localized AR (which may be evaluable in CTCs as early as
1 week after therapy initiation) is prognostic for better outcomes.
This clinical experience corroborates previous laboratory studies
showing that taxanes can inhibit AR nuclear trafﬁcking via sta-
bilization of microtubules.6,7,9 How prostate cancer cells manip-
ulate this mechanism of action to resist DTE and the differences
between sensitivity to docetaxel versus cabazitaxel have yet to be
determined. Interestingly, b-tubulin point mutations have been
shown to confer resistance to paclitaxel, but not docetaxel, sug-
gesting that single point mutations may affect one taxane but not
others, despite a shared binding site.24-26
A
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Time (months)
63 59 56 47 42 38 36 34 31 30 25 25 18 15 13 5 2 1 1
Pr
og
re
ss
io
n-
Fr
ee
Su
rv
iv
al
 (P
ro
ba
bi
lit
y)
No. at risk
Median: 9.07 months
95% CI, 4.93 to 11.70
B
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
63 61 60 58 53 51 51 48 47 44 40 39 35 31 28 16 12 10 8
Ov
er
al
l
Su
rv
iv
al
 (P
ro
ba
bi
lit
y)
No. at risk
Time (months)
Median: NR
95% CI, 14.03 to NR
Fig 2. (A) Progression-free survival (all patients). (B) Overall survival (all patients). NR, not reached.
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Fig 3. Representative high-resolution images of circulating tumor cells captured
by geometrically enhanced differential immunocapture with (A) high and (B) low
percent androgen receptor (AR) nuclear localization as assessed by quantita-
tive image analysis. Immunoﬂuorescence staining for AR is indicated in green.
4’,6-Diamidino-2-phenylindole staining for DNA (nucleus) is indicated in blue (arrow).
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There are several clinical implications of this study. First,
although this study is not sufﬁcient to change the standard of care
among patients with mCRPC receiving taxane therapy, it suggests
that a treatment switch from one taxane to the othermay be worthy
of further investigation in patients who do not achieve a $ 30%
PSA reduction within the ﬁrst 12 weeks. Importantly, prior studies
have shown that men who do not achieve a 30% PSA decline by
week 12 of treatment have a poorer survival with docetaxel and
cabazitaxel than those who do.27,28 Second, it suggests that changes
in CTC-speciﬁc ARNL observed as early as 1 week after therapy
initiation may be a potentially more sensitive and speciﬁc bio-
marker of subsequent clinical response than 12-week PSA changes.
Future prospective studies should evaluate whether switching
taxane therapy early on the basis of a CTC biomarker may improve
outcomes compared with switching therapy on the basis of PSA
trends (or not switching therapy at all).
This study has several limitations. First, on the basis of its
design and relatively small sample size, it used an assumption that
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Fig 4. Greatest prostate-speciﬁc antigen (PSA) change from baseline at any time on study according to mean percent androgen receptor nuclear localization (%ARNL) at
cycle 1 day 8 (C1D8; after 1week of therapy). (A) Comparison of the lower three quartiles versus the upper quartile ofmean%ARNL at C1D8 (n = 31); PSA$ 50%decrease
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Table 2. Summary of Key TEAEs
TEAE
All Grades, No. of Patients (%) Grade 3 or 4, No. of Patients (%)
Cabazitaxel Throughout
(n = 19)
Docetaxel Throughout
(n = 27)
Both Drugs
(n = 15)
Cabazitaxel Throughout
(n = 19)
Docetaxel Throughout
(n = 27)
Both Drugs
(n = 15)
Key TEAEs
Diarrhea 12 (63.2) 13 (48.1) 9 (60.0) 1 (5.3) 0 0
Neuropathy, peripheral 6 (31.6) 9 (33.3) 3 (20.0) 0 0 2 (13.3)
Febrile neutropenia 3 (15.8) 5 (18.5) 0 3 (15.8) 4 (14.8) 0
Dysgeusia 2 (10.5) 4 (14.8) 3 (20.0) 0 0 0
Paresthesia 2 (10.5) 3 (11.1) 3 (20.0) 0 0 0
Asthenia 0 4 (14.8) 1 (6.7) 0 1 (3.7) 0
Other TEAEs in $ 10% of patients
Fatigue 13 (68.4) 18 (66.7) 10 (66.7) 3 (15.8) 2 (7.4) 3 (20.0)
Nausea 10 (52.6) 8 (29.6) 7 (46.7) 0 0 1 (6.7)
Alopecia 5 (26.3) 9 (33.3) 5 (33.3) 0 0 0
Decreased appetite 4 (21.1) 8 (29.6) 4 (26.7) 1 (5.3) 0 1 (6.7)
Abdominal pain 4 (21.1) 7 (25.9) 4 (26.7) 0 0 0
Constipation 6 (31.6) 3 (11.1) 5 (33.3) 0 0 0
Vomiting 7 (36.8) 3 (11.1) 4 (26.7) 0 0 0
Edema, peripheral 3 (15.8) 7 (25.9) 4 (26.7) 0 0 0
Dyspepsia 3 (15.8) 3 (11.1) 3 (20.0) 0 0 0
Dizziness 3 (15.8) 3 (11.1) 3 (20.0) 0 0 0
Laboratory parameter
Anemia 18 (94.7) 23 (85.2) 14 (93.3) 1 (5.3) 1 (3.7) 0
Thrombocytopenia 5 (26.3) 3 (11.1) 3 (20.0) 0 0 0
Leukopenia 4 (21.1) 4 (14.8) 4 (26.7) 2 (10.5) 1 (3.7) 0
Neutropenia 3 (15.8) 2 (7.4) 1 (6.7) 2 (10.5) 1 (3.7) 0
Abbreviation: TEAE, treatment-emergent adverse event.
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the activity of docetaxel and cabazitaxel is similar in chemotherapy-
naı¨ve patients with mCRPC. The limited sample size affected
follow-up biomarker time points even more profoundly, especially
with respect to paired samples. For example, not all patients with
evaluable baseline CTCs had paired samples available at C1D8,
possibly as a result of elimination of tumor cells from the circu-
lation by effective chemotherapy. Second, the length of follow-up
was relatively short, and we were not able to assess radiographic
PFS or OS reliably or determine whether any biomarker signature
was associated with improved survival. Third, the trial was not
designed to deﬁnitively answer the question of whether a taxane
switch (based on either PSA criteria or CTC-derived ARNL cri-
teria) was superior with respect to OS than no switch at all. Such
questions should form the basis for future studies randomly
assigning patients to a switch strategy versus no switch. Finally, our
ability to draw ﬁrm conclusions about the value of the early-switch
strategy was limited by the small number of patients who un-
derwent a taxane switch (n = 15), as a result of the signiﬁcant
activity of both agents in the chemotherapy-naı¨ve mCRPC setting.
Therefore, the study was unable to deﬁnitively prove that the
taxane switch was responsible for subsequent PSA responses in
those switching therapy or that biomarker modulation after switch
induced those PSA responses.
All patients in the safety population experienced at least one
TEAE. Grade 3 or 4 TEAEs were reported in 51% of patients; of
these, the most frequently reported were febrile neutropenia and
fatigue. No grade 3 or 4 febrile neutropenia events were reported in
patients who switched taxane, although it should be noted that
there was only a small number of patients in this subgroup. In
general, the safety proﬁles of cabazitaxel and docetaxel were
consistent with previous studies, and no new safety concerns were
identiﬁed.
In conclusion, to our knowledge, this is the ﬁrst prospective
study to evaluate the beneﬁt of an early switch in taxane therapy on
the basis of the absence of a$ 30% PSA response after 12 weeks of
therapy, and it suggests improved outcomes compared with his-
torical controls with this approach. To our knowledge, it is also
the ﬁrst study to incorporate real-time on-treatment measure-
ments of %ARNL and MTB from CTCs, indicating that these early
measures may be associated with beneﬁt in men treated with
taxanes. Further dedicated prospective randomized trials focusing
on a taxane switch using integral biomarkers are warranted.
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